Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback